- Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes. Sakaguchi, Masahiro; Shime, Nobuaki; Iguchi, Naoya; Kobayashi, Atsuko; Takada, Koji; Morrow, Lee // Journal of Infection & Chemotherapy (Springer Science & Business;Aug2013, Vol. 19 Issue 4, p599
Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed...
- Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia. Torres, Antoni; Ferrer, Miquel; Badia, Joan Ramón // Clinical Infectious Diseases;8/1/2010 Supplement 1, Vol. 51, pS48
Hospital-acquired pneumonia is the second most frequent nosocomial infection and the first in terms of morbidity, mortality, and cost. In recent years, international societies and, most recently, the American Thoracic Society jointly with the Infectious Disease Society of America, have developed...
- The Argument against Using Quantitative Cultures in Clinical Trials and for the Management of Ventilator-Associated Pneumonia. Niederman, Michael S. // Clinical Infectious Diseases;8/1/2010 Supplement 1, Vol. 51, pS93
Quantitative cultures have been proposed as the most accurate way to both establish the presence of ventilator-associated pneumonia (VAP) and define the etiologic pathogen. Although the clinical diagnosis of VAP has been much maligned, it may be very accurate, particularly if it is objectively...
- The roles of the newer macrolide antibiotics in treating community-acquired pneumonia. Segreti, John // Modern Medicine;Oct94, Vol. 62 Issue 10, p30
Evaluates the efficacy of macrolide antibiotics clarithromycin and azithromycin in treating community-acquired pneumonia. Organisms that cause community-acquired pneumonia; Symptoms of community-acquired pneumonia; Pharmacokinetic differences; Efficacy comparisons.
- Antibiotic for pneumonia, bronchitis. // Geriatrics;Apr97, Vol. 52 Issue 4, p36
Discusses information about Sparfloxacin, a broad-spectrum antibiotic indicated for the treatment of pneumonia and bronchitis caused by designated susceptible microorganisms. How sparfloxacin is similar to erythromycin, cefaclor and ofloxacin; Recommended dosage for taking sparfloxacin;...
- Measuring and Interpreting Associations between Antibiotic Use and Penicillin Resistance in Streptococcus pneumoniae. Lipsitch, Marc // Clinical Infectious Diseases;4/1/2001, Vol. 32 Issue 7, p1044
Presents information on the measurement and interpretation of associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Problems with penicillin resistance; Relationship measurement in pneumococci; Treatment and resistance; Interpretation of studies; Discussion...
- Alternative Antibiotics. Eisen, Gail S. // Pharmaceutical Executive;Oct2001, Vol. 21 Issue 10, p110
Deals with a study which examined the effectiveness of ketolide antibiotics against Streptococcus pneumoniae. Variety of antibiotics used against the bacteria; Susceptibility of the bacteria to telithromycin, a member of the ketolide antibiotics family.
- Community-acquired pneumonia: New outpatient guidelines based on age, severity of illness. Whitson, Brian; Campbell Jr., G. Douglas // Geriatrics;Mar94, Vol. 49 Issue 3, p24
Discusses the American Thoracic Society's (ATS) guidelines on the outpatient management of community-acquired pneumonia (CAP). Actual incidence of CAP; Efficacy of antibiotic therapy; Incidence of mortality and morbidity; Difficulty in identifying potential pathogens.
- New guidelines on hospital-acquired pneumonia. // Patient Care;7/15/1996, Vol. 30 Issue 12, p13
Reports on the consensus statement issued by the American Thoracic Society on initial treatment of hospital-acquired pneumonia. Cases per admission; Cause of nosocomial death; Categories of patients for treatment; Selection between monotherapy and combination treatment; Controversies in...